In Texas today, ibogaine is not a routine, legal treatment. The “best treatment nearby” usually means vetted Mexico-based medical programs or entry into U.S. clinical trials, with Texas now funding a major research push. This page explains the current landscape, safety, costs, and how Texans can approach ibogaine for addiction treatment with high caution and clarity.
Use this three-part structure to navigate decisions from Texas: understand legality, choose an access pathway, and prepare for safety and aftercare. Each element below reflects what is possible in 2026—not promises of outcomes.
Ibogaine remains Schedule I in the U.S. and is not FDA-approved. Texans cannot receive commercial ibogaine treatment in-state; access is limited to regulated clinical trials under medical oversight, or lawful programs abroad.
Texas-funded ibogaine clinical trials
Planned multicenter research window
Institutions in the Texas consortium
Typical active treatment window abroad
As of 2026, ibogaine is a Schedule I substance under U.S. federal law and is not FDA-approved. Commercial clinics offering ibogaine in Texas do not operate legally; access in-state is limited to research settings with Investigational New Drug (IND) authorization and institutional oversight.
Texas, however, has become the largest public investor in ibogaine research in the U.S., committing approximately $50 million to a two-year, multicenter program engaging more than ten institutions—including UTHealth Houston and UTMB Health—to study conditions such as opioid use disorder, traumatic brain injury, PTSD, and depression.
For residents exploring trial access, the Texas HHS ibogaine clinical trials resource is a practical, state-hosted starting point to understand eligibility and where studies may be enrolling.
Mexico-based medical programs are the most common “nearby” path for Texans. Typical pricing runs about $6,000–$12,000 USD for a 5–7 day program, while Costa Rica retreats often range $8,000–$15,000 USD. Programs usually describe an 8–14 hour dosing phase within a 24–72 hour overall treatment and recovery window. Quality, credentials, and on-site medical readiness vary widely—due diligence is essential.
U.S.-authorized research pathways include FDA-regulated trials now being advanced with Texas state support. These studies focus on public health priorities such as addiction, veteran-related brain injury, PTSD, and depression. Trial participation involves rigorous screening, defined protocols, and formal follow-up.
What ibogaine is being studied for: opioid use disorder, stimulant and alcohol use disorders, PTSD, depression, and traumatic brain injury. Reported success rates in uncontrolled or retrospective accounts vary; some doctors have reported 50%–80% improvements, while one 2017 study cited 30% remaining off opioids post-treatment and 11% achieving full abstinence. Treat these figures cautiously—they are not guarantees and often reflect small or heterogeneous samples.
Safety is the controlling issue. In reviews covering 1990–2008, at least 19 deaths were linked to ibogaine exposure, and one MAPS-cited estimate places mortality risk as high as 1 in 300. Risk management must include medical screening, medication interaction review, continuous monitoring during dosing, and conservative discharge planning.
Recovery and integration extend beyond the dosing window. Many people report lingering physiological and psychological changes for days to weeks; reading about ibogaine aftereffects can help set realistic expectations and inform your support plan at home.
Disclose all meds and history; verify cardiac and liver evaluations are performed.
Ensure continuous observation during the 8–14 hour dosing phase and immediate access to higher care if needed.
Plan follow-up with addiction medicine, therapy, and peer support for at least several weeks.
Public messaging around the Texas consortium has highlighted remission ranges (83%–90%) across PTSD, depression, anxiety, and cravings after one session in some contexts. These figures are directional, not definitive, and underline why Texas is investing in rigorous trials.
In one 2017 study, about 30% of patients remained off opioids after treatment and 11% reached full abstinence. Methodology and follow-up periods vary—interpret cautiously and as part of a broader care plan.
Historical safety reviews cited at least 19 deaths (1990–2008) and an estimated mortality risk up to 1 in 300 in some sources. These underscore the need for careful screening and clinical oversight wherever possible.
If you prefer regulated care, your most direct path is to confirm eligibility for U.S. trials operating in or connected to Texas. If traveling abroad, vet programs thoroughly, confirm safety protocols, and map your aftercare before booking. For additional context on transitions and integration, read about ibogaine aftereffects and set a conservative timeline for recovery support.
When evaluating programs or studies, keep your decision anchored to goals (detox, craving relief, trauma symptoms), safety (screening and monitoring), and support (medical and psychosocial follow-up). This approach reflects the state’s research emphasis while respecting current legal limits in Texas.